NYSE:BMYPharmaceuticals
Bristol Myers Squibb Hengrui Deal Expands Pipeline And Valuation Upside Potential
Bristol Myers Squibb (NYSE:BMY) announced a global collaboration and licensing deal with Hengrui Pharma valued at up to $15.2 billion.
The agreement covers joint development of 13 early stage assets across oncology, hematology, and immunology.
The partnership is designed to expand Bristol Myers Squibb's pipeline and tap China based drug discovery for global markets.
Bristol Myers Squibb is entering this partnership with Hengrui at a time when the stock trades around $56.39 per share and has...